Epigenetic regulation lies at the heart of cellular identity in a multicellular organism, as each cell carries the same DNA but expresses a highly choreographed set of genes 1,2 . Each cell type has a unique epigenome, characterized by specific modifications of histone proteins and DNA methylation patterns that divide the genome into active, poised and silent domains. Members of the histone-lysine N-methyltransferase 2 (KMT2; also known as mixed-lineage leukaemia (MLL)) family methylate histone H3 on lysine 4 (H3K4) to promote genome accessibility and transcription. The KMT2 family is highly conserved, having evolved from an ancient lineage of proteins present in unicellular eukaryotes 3, 4 . In cancer, transcriptional dysregulation subverts cellular identity by aberrantly linking proliferation and migration programmes present during embryonic development to an otherwise differentiated, often quiescent, phenotype required for postnatal homeostasis 5, 6 . Dysregulation or mutation of the KMT2 family in human cancer exemplifies how this can occur: in haematopoietic cells, translocations of KMT2A (also known as MLL, MLL1, ALL-1 and HRX) result in oncogenic fusion proteins that recruit the H3K79 methyltransferase DOT1L. This changes the epigenetic identity of the cells and drives a subset of infantile and adult leukaemias 7, 8 . Intense efforts have been devoted to investigating function and regulation of the KMT2 family, driven in part by the historic discoveries of KMT2A rearrangements as causes of MLL 9-12 and of the H3K4 methyltransferase activity of KMT2A 13, 14 . In this Review we discuss the key advances that have allowed us to define how KMT2 proteins function within multimeric complexes, the subunits of which modulate KMT2 activity on chromatin. Recent exome-sequencing studies have shown that KMT2 dysregulation extends well beyond a rare cancer like KMT2A-rearranged MLL 15, 16 . Instead, KMT2 family mutations are among the most frequent alterations in human cancer 17 and are associated with some of the most common and deadly solid tumours, such as lung 15 and colon 16 carcinomas. Finally, we discuss the development of inhibitors that target cofactors in KMT2-containing complexes and highlight the promise of these agents against a variety of human cancers. Although much of what is known for KMT2 enzymes was initially characterized in yeast 3 , owing to limited space, this Review focuses on the KMT2 family of proteins in higher eukaryotes.
Epigenetic regulation lies at the heart of cellular identity in a multicellular organism, as each cell carries the same DNA but expresses a highly choreographed set of genes 1, 2 . Each cell type has a unique epigenome, characterized by specific modifications of histone proteins and DNA methylation patterns that divide the genome into active, poised and silent domains. Members of the histone-lysine N-methyltransferase 2 (KMT2; also known as mixed-lineage leukaemia (MLL)) family methylate histone H3 on lysine 4 (H3K4) to promote genome accessibility and transcription. The KMT2 family is highly conserved, having evolved from an ancient lineage of proteins present in unicellular eukaryotes 3, 4 . In cancer, transcriptional dysregulation subverts cellular identity by aberrantly linking proliferation and migration programmes present during embryonic development to an otherwise differentiated, often quiescent, phenotype required for postnatal homeostasis 5, 6 . Dysregulation or mutation of the KMT2 family in human cancer exemplifies how this can occur: in haematopoietic cells, translocations of KMT2A (also known as MLL, MLL1, ALL-1 and HRX) result in oncogenic fusion proteins that recruit the H3K79 methyltransferase DOT1L. This changes the epigenetic identity of the cells and drives a subset of infantile and adult leukaemias 7, 8 . Intense efforts have been devoted to investigating function and regulation of the KMT2 family, driven in part by the historic discoveries of KMT2A rearrangements as causes of MLL [9] [10] [11] [12] and of the H3K4 methyltransferase activity of KMT2A 13, 14 . In this Review we discuss the key advances that have allowed us to define how KMT2 proteins function within multimeric complexes, the subunits of which modulate KMT2 activity on chromatin. Recent exome-sequencing studies have shown that KMT2 dysregulation extends well beyond a rare cancer like KMT2A-rearranged MLL 15, 16 . Instead, KMT2 family mutations are among the most frequent alterations in human cancer 17 and are associated with some of the most common and deadly solid tumours, such as lung 15 and colon 16 carcinomas. Finally, we discuss the development of inhibitors that target cofactors in KMT2-containing complexes and highlight the promise of these agents against a variety of human cancers.
Although much of what is known for KMT2 enzymes was initially characterized in yeast 3 , owing to limited space, this Review focuses on the KMT2 family of proteins in higher eukaryotes.
Structural insights into the regulation of KMT2s
The KMT2 family is highly conserved throughout eukaryotes 3, 4 . Three subgroups of KMT2 are present in Drosophila melanogaster: trithorax (Trx), trithorax-related (Trr) and Set1 (REF. 4) . Chromosomal duplication during mammalian evolution resulted in two paralogues in each KMT2 subgroup 18 . They are: trx-related KMT2A and KMT2B (also known as Mll2 in mice, MLL4 in humans; andWBP7); trr-related KMT2C (also known as MLL3 and HALR) and KMT2D (also known as Mll4 in mice and MLL2 in humans; ALR); and Set1-related KMT2F (also known as SET1A and SETD1A) and KMT2G (also known as SET1B and SETD1B) (FIG. 1a) . KMT2E (also known as MLL5) is more homologous to the SET3 family, and the protein it encodes has no intrinsic methyltransferase activity 19 ; therefore, KMT2E is not included in this Review. KMT2 proteins reside in large, multisubunit complexes composed of unique sets of interacting proteins 14, [20] [21] [22] [23] [24] [25] (TABLE 1) . Despite the diversity, four subunits (that is, WD repeat protein 5 (WDR5), retinoblastomabinding protein 5 (RBBP5), ASH2L and DPY30) are commonly found in all KMT2 complexes. Biochemical reconstitution shows that WDR5, RBBP5 and ASH2L form a stoichiometric core entity 26 (FIG. 1b) that stably interacts with the KMT2 enzymes and enhances their otherwise weak activities (~50-500-fold) 26, 27 . Dimeric DPY30 further contributes to overall KMT2 activity on the H3 peptide by approximately twofold 27 . A threedimensional view of the KMT2A core complex shows that the catalytic SET domain is positioned in the centre, with the RBBP5-WDR5 and ASH2L-DPY30 pairs on opposite ends of the SET domain 28 . Although the atomicresolution structure of the KMT2 core complex has not yet been reported, X-ray crystal structures of most individual components and key interaction interfaces among them have been solved [29] [30] [31] [32] [33] [34] [35] [36] . They show that the KMT2A SET domain adopts a conformation that is ineff icient in catalysis 36 , which necessitates a conformational change by interacting with the WDR5-RBBP5-ASH2L core entity.
In vitro biochemical studies show that ASH2L and RBBP5 form a stable heterodimer 26 , which is required for the activities of all KMT2 complexes 26, 37 . It is likely that the RBBP5-ASH2L heterodimer facilitates and stabilizes the interaction between the SET domain and the KMT2 substrates 38 . Although transient interactions between RBBP5-ASH2L and the KMT2A SET domain are documented 38, 39 , WDR5 stably bridges RBBP5 and KMT2A via direct binding to a conserved WDR5-interacting motif in KMT2A 29, 40 and a Val-Asp-Val motif in RBBP5 (REF. 41 ). Disruption of WDR5-KMT2A binding by WDR5-interacting peptides (or their derivatives) leads to disintegration of the KMT2A complex and inhibition of KMT2A catalytic activity in vitro [42] [43] [44] . Interestingly, despite conservation of the core entity, WDR5 is not necessary in regulating other KMT2 complexes 45 . The unique regulation of KMT2A activity by WDR5 has recently been exploited to develop specific KMT2A methyltransferase inhibitors (discussed below) [45] [46] [47] . In addition to being regulated by core components, activities of KMT2A and KMT2B are also regulated by taspase 1, a threonine aspartase 48 . Following taspase 1-mediated proteolysis (FIG. 1a) , the resulting large amino-terminal fragment and smaller carboxy-terminal fragment associate through FY-rich N-terminal (FYRN) and FYR C-terminal (FYRC) domains to generate a functional, non-covalent heterodimeric complex 48, 49 . Although it is still being debated whether the cleavage per se is important 50 , the intramolecular interactions facilitated by FYRN and FYRC dimerization are able to regulate KMT2A activity and expression of target genes in cells 48, 50 .
Substrate specificity of the KMT2 enzymes The requirement of WDR5 for overall enzymatic activity is only one of many distinguishing biochemical properties among KMT2 enzymes. The KMT2 core complexes also diverge in their in vitro substrate specificity. Mass spectrometry studies show that the recombinant KMT2F and KMT2G core complexes are capable of nucleosomal H3K4 monomethylation (H3K4me1), dimethylation (H3K4me2) and trimethylation (H3K4me3), similar to yeast Set1 (REF. 3 ). Recombinant KMT2A and KMT2B Figure 1 | Metazoan KMT2 family histone methyltransferases. a | Schematic representation of the domain structures for each histone-lysine N-methyltransferase 2 family (KMT2) member. KMT2A and KMT2B have the consensus DVDD or GVDD sites (indicated by arrows) that are cleaved by taspase 1, of which there are two conserved sites for KMT2A and one for KMT2B. This cleavage site is a unique feature for this KMT2 subgroup. The resulting large amino-terminal fragment and smaller carboxy-terminal fragment subsequently associate through FY-rich N-terminal (FYRN) and FYR C-terminal (FYRC) domains to generate a functional, non-covalent heterodimer. KMT2C and KMT2D contain two clusters of plant homeotic domains (PHDs), as well as the juxtaposed FYRN, FYRC and SET domains on the C terminus. One high mobility group I (HMG-I) binding motif and multiple nuclear receptor interacting motifs (LXXLL) are present in the protein sequences. These motifs are frequently found in transcription factors and cofactors. The PHD4-6 domains of KMT2C and KMT2D are able to bind to unmethylated and to asymmetrically dimethylated histone H4 arginine 3 (H4R3me0 and H4R3me2a, respectively). This supports a coordinated function with protein arginine methyltransferases 53 . KMT2F and KMT2G are the smallest KMT2 subgroup and contain an N-terminal RNA recognition motif (RRM) and a C-terminal N-SET domain, which interact with WD repeat protein 82 (WDR82) and ubiquitylated histone H2B respectively. b | Schematic representation of interactions among KMT2A core subunits as well as their interactions with chromatin. KMT2A core complex is stabilized by pair-wise interactions between: the WDR5-interacting (WIN) motif on KMT2A and WDR5; WDR5 and the VDV motif of retinoblastoma-binding protein 5 (RBBP5); RBBP5 and ASH2L; and ASH2L-DPY30. Furthermore, KMT2A is stabilized on chromatin through multivalent interactions that include interactions of the AT-hook and CXXC domain with the AT-rich sequence and unmethylated CpG dinucleotides 73 , respectively, as well as interactions between PHDs and bromodomains (bromo) with trimethylated histone H3 lysine 4 (H3K4me3) and acetylated lysine residues, respectively 75 . The coupling of the enzyme with binding domains for its methylation products is important for feedforward maintenance of H3K4me in cells. Transient interactions between SET and the histone H3 tail, as well as the PHD of ASH2L and ubiquitin (Ub) have also been reported. aa, amino acid; CBP, CREB-binding protein; TAD, transactivation domain.
AT-rich sequence
A DNA sequence with a higher frequency of adenosine and thymidine that can be found in specific genomic regions such as transcription start sites (TATA boxes) or replication initiation sites in bacteria. It can be specifically bound by several protein motifs such as AT-hook, HMG motif and B-box zinc finger.
CpG dinucleotides
A cytosine and a guanine nucleotide separated by one phosphate. The frequency of CpG dinucleotides in human genomes is extremely low (~1%), and most are methylated to form 5-methylcytosine. A relatively high level of unmethylated CpG dinucleotides is usually associated with promoters of actively transcribed genes.
core complexes are able to monomethylate and dimethylate H3, but have low trimethylation activity 42, 51 . By comparison, the recombinant KMT2C and KMT2D core complexes are predominantly monomethyltransferases (S. Y. Lee and Y.D., unpublished observations). The basis for distinct substrate specificity remains poorly understood and will benefit from future structural studies of respective KMT2 SET domains. Notably, the substrate specificities of the bacterially expressed core complexes are not always consistent with those of purified holocomplexes 20,21, [52] [53] [54] , or of the reconstituted core complex in insect cells 26 . It is likely that additional factors may contribute to KMT2 regulation in the holocomplex, or that KMT2s are subject to additional regulation by protein post-translational modifications. For example, it has been reported that KMT2A and KMT2F (but not KMT2C) are regulated by histone H2B ubiquitylationmediated trans-activation 51 . Furthermore, SUMOylation of RBBP5 substantially inhibits KMT2A activity in cells by disrupting its association with ASH2L 55 . Given the extensive post-translational modifications of KMT2 core subunits revealed by recent proteomic studies, it will be of interest to determine whether these modulate the substrate specificity of the KMT2 complexes.
Subunit compositions of the KMT2 enzymes
Label-free quantitative mass spectrometry shows that the subunit compositions of KMT2 complexes have a high degree of heterogeneity within individual cells 56 . In fact, one distinguishing feature among the three KMT2 subgroups is their unique set of associating transcription factors and cofactors (TABLE 1) . Specifically, menin (encoded by multiple endocrine neoplasia type 1 (MEN1) 21 ) and LEDGF (lens epithelium-derived growth factor; encoded by PSIP1) 57, 58 are unique subunits for KMT2A and KMT2B that mediate their recruitment to target genes via interactions with transcription factors such as oestrogen receptor-α (ERα) 59 . PTIP (Paired box (PAX) transactivation-domain interacting protein; also known as PAXIP) and NCOA6 (nuclear receptor coactivator 6) are unique subunits in the KMT2C and KMT2D complexes 20, 22, 60 that interact with the PAX family of transcription factors 60 , as well as with nuclear receptors such as PPARγ (peroxisome proliferator-activated receptor-γ) and LXR (liver X receptor) 20 . 69 and OCT4 (octamer-binding transcription factor 4; also known as POU5F1) 70 . These interactions probably contribute to context-dependent functions of the KMT2 complexes.
The chromatin binding of KMT2 complexes Distinct sets of interacting proteins underlie the largely variable distributions of KMT2 proteins throughout the genome (FIG. 2) . Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies show that KMT2F and KMT2G generally bind to transcription start sites 69 , whereas KMT2C and KMT2D are highly enriched at enhancers 52, 71 . Genome-wide binding sites for KMT2A and KMT2B are less clear, as recent studies have indicated that they bind to both gene promoters and enhancers 71, 72 . The patterns of genome-wide distribution of KMT2 proteins are consistent with the pattern of H3K4 methylation (H3K4me) states (that is, monomethylation, dimethylation or trimethylation), as expected for the substrate specificity of each KMT2 protein (FIG. 2) . They also underscore the intrinsic affinity of KMT2 proteins for different chromatin regions. For example, KMT2A and KMT2B contain the CXXC domains that bind to unmethylated CpG dinucleotides 73 -a common feature for a large subset of metazoan gene promoters 74 . The binding of KMT2A and KMT2B to gene promoters can be further stabilized by PHD3 (plant homeotic domain 3) and bromodomains, which bind to H3K4me3 and acetylated lysine residues, respectively, that are highly enriched around transcription start sites 75 . By contrast, KMT2C and KMT2D contain binding motifs (for example, high mobility group I (HMG-I) and LXXLL motifs) that are commonly found in transcription factors and cofactors 76, 77 . They also bind to unmethylated and asymmetrically dimethylated H4 arginine 3 (H4R3me0 and H4R3me2a, respectively) via PHD4, PHD5 and PHD6 (REF. 53 ). Consistent with the preferred binding of KMT2C and KMT2D at intergenic regions, these modifications are not necessarily enriched at gene promoters. The recruitment of KMT2 proteins to specific chromatin regions (for example, the homeobox A (HOXA) cluster) by long non-coding RNAs has also been reported 78, 79 . Despite this progress, many unanswered questions regarding KMT2 recruitment and chromatin binding remain. For example, confocal microscopy has revealed 
Unique subunits
CFP1, CXXC finger protein 1; HCF1, host cell factor 1; KMT, histone-lysine N-methyltransferase; NCOA6, nuclear receptor coactivator 6; PA1, PTIP associated 1; PTIP, PAX transactivationdomain interacting protein; RBBP5, retinoblastoma-binding protein 5; UTX, ubiquitously transcribed tetratricopeptide repeat, X chromosome; WDR, WD repeat-containing protein. . In addition, highly localized KMT2 proteins are often found in small areas within much broader H3K4me domains, especially at intergenic regions 52 . It is not clear how H3K4me is spread in these regions without concurrent spreading of the KMT2 enzymes. Furthermore, it is not clear whether KMT2 complexes are recruited as a whole to chromatin or assembled at target genes through step-wise recruitment. The prevalence of overlapping binding sites in the genome for only a subset of core subunits (for example, WDR5, ASH2L or KMT2) seems to support step-wise recruitment 66 . Alternatively, KMT2 subunits can bind to distinct regions near the target loci and methylate H3 through a scanning model 66 . These remaining questions warrant further studies.
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Physiological functions of KMT2 family enzymes
KMT2s in transcription regulation. The KMT2 family plays an important part in transcription regulation. KMT2 enzymes are enriched at multiple transcription regulatory regions, including at gene promoters and enhancers 3, 4 . Despite being the major enzymes for H3K4me, deletion of individual Kmt2 family genes in mouse embryonic fibroblasts leads to surprisingly few changes in overall gene expression 81 . However, KMT2C and KMT2D are crucial for the induction of transcriptome changes during adipogenesis and transdifferentiation of pre-adipocytes into myocytes 52 . Largescale KMT2-dependent transcriptome changes are also described during embryonic stem cell differentiation 70 , leukaemic transformation 45 or cellular response to external stimuli (for example, lipopolysaccharide 82 or retinoic acid 83 stimulation). These results support a dynamic and/or context-dependent requirement of KMT2s for proper gene expression.
Direct and causal functions of several KMT2s in transcription initiation have been elegantly demonstrated in vitro 25, 54, 84 and are further supported by KMT2-dependent RNA polymerase II binding at promoters and enhancers in various cells 52, 71 . The function of H3K4me3 in transcription has been extensively discussed 85, 86 . It generally involves the recruitment of a large repertoire of 'reader' proteins 87, 88 , which communicate the epigenetic changes to the basic transcription machinery, thereby leading to either productive transcription or gene repression 85, 86 . Despite the high level of H3K4me3 at active gene promoters, H3K4me3 alone does not necessarily dictate transcription outcome, given that reader proteins can be either co-activators or corepressors 87, 88 . Instead, a combinatorial readout that involves H3K4me3 and other histone modifications is more likely to be predictive 87 . H3K4me also contributes to transcription regulation by preventing ectopic silencing of euchromatin 89 , by facilitating pre-mRNA processing 90 and by regulating antisense transcripts 91 . ChIP-seq studies for genome-wide histone modifications show that H3K4me1 is perhaps the most important histone modification that marks the distal regulatory enhancers, which can be further divided into 'active' and 'poised' enhancers depending on H3K27 modifications 92, 93 . In fact, H3K4me1 enrichment is a widely used criterion to catalogue lineagespecific and developmental stage-specific enhancers owing to its remarkable fidelity 94, 95 . Recent studies show that the de novo establishment of H3K4me1-enriched lineage-specific enhancers foreshadows cell typespecific transcription programmes 94 . Dysregulation of enhancer activity leads to the disruption of the On the basis of histone-lysine N-methyltransferase 2 (KMT2) functional domains, their respective interactions with chromatin and their substrate specificities, it is envisioned that KMT2C and KMT2D are the predominant KMT2s at distal enhancers, whereas KMT2F and KMT2G are the major enzymes at gene promoters. KMT2A and KMT2B could function at both regulatory regions. The distribution of KMT2 enzymes in the genome is consistent with the distribution of histone H3 lysine 4 methylation; that is, H3K4me1 is a predominant histone mark at cell-type-specific distal regulatory enhancers and H3K4me3 is mainly found at actively transcribed gene promoters. Recruitment of KMT2s to different genomic regions is also facilitated by their interactions with sequence-specific transcription factors or RNA polymerase II (RNAPII), which leads to non-coding and coding transcription at enhancers and promoters, respectively. CFP1, CXXC finger protein 1; CGI, CpG island; H2B, histone H2B; PAF1C, RNA polymerase-associated factor 1 complex; TSS, transcription start site; Ub, ubiquitin; WDR82, WD40 repeat protein 82. precise spatiotemporal regulation of gene expression and, therefore, is linked to human cancers 96, 97 . Characterizing the functions of KMT2 enzymes at enhancers is an emerging field; it has recently been shown that KMT2C and KMT2D are the major histone methyltransferases responsible for H3K4me1 at adipocyte-and myocyte-specific enhancers 52 . They function to prime these enhancers, in coordination with lineage-specific transcription factors, by maintaining open chromatin structures and facilitating RNA polymerase II access 52 . H3K4me1 at macrophage-specific enhancers is catalysed by KMT2A and KMT2D and is required for active non-coding transcription at enhancers 71 . Deciphering KMT2-dependent enhancer regulation is likely to shed further light on the roles of these enzymes in development and human diseases. 101 . CGIs, which mark a major class of mammalian promoters that lack the core promoter elements 74 , can serve as a signalling module that locally influences chromatin structures through the recruitment of the CXXC domaincontaining KMT2 complexes (that is, those with KMT2A, KMT2B, KMT2F or KMT2G) for de novo accumulation of H3K4me3 (REF. 102 ). Reciprocally, high levels of H3K4me3 and concurrent ongoing transcription protect unmethylated CGIs in the early embryo from de novo DNA methylation 102 . In leukaemia cells, binding to CGIs by KMT2A protects CpG clusters within HOXA9 from methylation [103] [104] [105] . Loss-of-function mutation in the KMT2A CXXC domain leads to increased DNA methylation at CGIs, silencing of HOXA9 and subsequent inhibition of leukaemia cell growth 105 . Furthermore, unmethylated CGIs ensure that KMT2F and KMT2G localize to gene promoters, preventing ectopic KMT2F-and KMT2G-binding at enhancers and consequent aberrant transcriptional activity 106 . Recently, interplay between KMT2 and the DNA methylcytosine dioxygenases TET2 and TET3 has been reported 107 . TET2 and TET3 promote GlcNAcylation of host cell factor 1 (HCF1) by the O-GlcNAc transferase (OGT), which is important for KMT2F-mediated H3K4me3 (REF. 107 ). Functional couplings of TET2 and TET3 (which are responsible for DNA 5-hydroxymethylation) to KMT2-mediated H3K4 methylation are intriguing and clearly warrant further investigation.
Regulation of KMT2s during cell cycle and development. In vivo functions of KMT2 family enzymes are context-dependent and dynamic
. This is, at least in part, due to the regulatory proteolysis of KMT2s. It has been reported that KMT2A and its D. melanogaster homologue Trx remain associated with DNA during DNA replication and mitosis to ensure perpetuation of transcriptional states 98, 108 . Despite S phase and M phase bookmarking, KMT2A is degraded at G1-S and M-G1 transitions during the cell cycle by E3 ubiquitin ligases SKP1-cullin 1-F-box protein (SCF) SKP2 and anaphase-promoting complex (APC/C) CDC20 , respectively [109] [110] [111] . Furthermore, the KMT2A level is tightly regulated by ankyrin repeat and SOCS box-containing protein 2-mediated degradation during haematopoietic differentiation 110 . The PHD2s of KMT2A and KMT2B also have intrinsic E3 ubiquitin ligase activity 109 . Importantly, the regulatory proteolysis of KMT2A is disrupted in leukaemogenic KMT2A fusion proteins, indicating the importance of KMT2A turnover in a physiological context 112 . Proteolytic turnover for other KMT2 domains has not yet been studied. A recent study showed that the stability of yeast Set1 could be regulated by the level of cellular H3K4me 113 . Whether similar feedback control exists for KMT2 in higher eukaryotes remains to be determined. Multi-level regulation of KMT2 activity ensures tight spatio temporal control of H3K4me, which is a necessity in higher eukaryotes.
Box 1 | KMT2 enzymes in development
A developmental role for the histone-lysine N-methyltransferase 2 (KMT2) family has been defined by humans and transgenic mice carrying mutant alleles in KMT2 family genes. Interestingly, homozygous deletion of each mouse Kmt2 family member results in a severe but distinct phenotype, indicating unique functional specification. Kmt2f is required at the earliest stage of development, as its deletion leads to gastrulation failure and embryonic lethality at embryonic day 5.5 (E5.5). In vitro studies show that Kmt2f is essential for the proliferation of embryonic stem cells, epiblast stem cells and neural stem cells, and is required for induced pluripotency 164 . By contrast, homozygous deletion of all other KmtMT2 members leads to lethality at a late stage of development. Widespread developmental defects have been reported for constitutive homozygous deletion of Kmt2b and Kmt2g, and these mice die around E10.5 and E11.5, respectively [126] [127] [128] 164 . Most organs and structures arise normally and no major morphological defects are reported except growth retardation [126] [127] [128] . Deletion of Kmt2d leads to embryonic lethality around E9.5 (REF. 52 ). Although the developmental defects of Kmt2d are not yet defined, conditional deletion of Kmt2d in somitic precursor cells leads to reduced brown adipose tissue and muscle mass 52 . Germline homozygous, but not heterozygous, deletion of Kmt2a and Kmt2c results in specific developmental defects. The abnormalities are mostly in axial skeleton patterning and definitive haematopoiesis for Kmt2a [165] [166] [167] and reduced white adipose tissue for Kmt2c 168 . The essential functions of the KMT2 family in development may not be due to the SET domain activity, as mice expressing Kmt2a lacking the SET domain are viable with only minor defects 169 , and mice expressing Kmt2c lacking the SET domain are born live, albeit at lower-than-expected Mendelian ratio 170 . Combinatorial deletion of the closely related SET domains of each KMT2 subgroup, to rule out the essential but redundant functions of histone H3 lysine 4 methylation (H3K4me) activities within each subgroup, has not been performed. The developmental requirement of KMT2 genes can be highly specific and transient. For example, Kmt2b deletion before E10.5 and after E11.5 has different consequences, as only deletion after E11.5 results in diabetic live-born mice 171 . Kmt2b deletion in adults results in defects such as sterility 128 . Similarly, conditional Kmt2a deletion has weaker effects in the adult haematopoietic system relative to deletion in utero 167, 172 . Transition of the major enzyme for global H3K4me3 from KMT2B to KMT2F has also been reported during inner cell mass formation 164 . KMT2 mutations span a diverse set of cancers Exome sequencing of human tumours has revealed a surprising variety of disease-specific mutations in the KMT2 family 17 . Although previous analyses had mainly focused on KMT2A somatic rearrangements in MLL, newly identified KMT2 mutations greatly expand the potential role of KMT2 genes in cancer 17 . An analysis of the nearly 2,200 somatic mutations in KMT2 family genes in cancers in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (TABLE 2) , together with recent in vivo modelling of KMT2s in disease, provides tantalizing clues to the pathogenesis of KMT2-driven cancers, and to the development of novel cancer therapeutics.
KMT2A. KMT2A rearrangements, tandem duplications and copy number amplifications have been extensively studied and thoroughly discussed in the context of MLL 7, 114 
. In comparison, mutations in the KMT2A coding region are under-represented in haematopoietic and lymphoid malignancies, accounting for only 2.3% of 305 non-synonymous mutations in the KMT2A region in the COSMIC database (TABLE 2) .
However, recent profiling studies show that mutations in the KMT2A region are prevalent in a large range of solid tumours (for example, colon, lung, bladder, endometrial and breast cancers) 15, [115] [116] [117] . Most KMT2A mutations are nonsense and frameshift mutations that lead to the early termination of translation, with ~40% of these resulting in truncated proteins that have no methyl transferase activity. Truncations that affect PHDs and CXXC domains account for 18% and 9% of mutations, respectively. Missense mutations or in-frame deletions in the SET, WDR5-interacting and CXXC domains and PHDs of KMT2A are also reported, albeit at much lower frequencies. It remains unclear how missense mutations in cancers affect the functions of the specific domains and/or the overall stability of the protein. Although zygosity remains unknown for 60% of total reported KMT2A mutations, heterozygous mutations account for nearly all the known mutations for which zygosity has been determined. Thus, similar to that seen in KMT2A-rearranged MLL and KMT2A germline mutations
, it seems that at least one wild-type KMT2A allele remains intact in the vast majority of cancers. 
Domain affected
KMT2A
• Large intestine
*This information was derived from the authors' analysis of the Catalogue of Somatic Mutations in Cancer (COSMIC) database. All information was accessed on 25 August 2014, and search terms for genes included MLL (KMT2A), MLL4 (KMT2B), MLL3 (KMT2C), KMT2D, SETD1A (KMT2F) and SETD1B (KMT2G). All synonymous non-coding and coding mutations were excluded. The histological origin of tumours was broad and distribution was gene-specific. COSMIC data also included zygosity, and many other characteristics that detailed each sample deposited in the database. The amino acid change for each KMT2 was then mapped to the Universal Protein Resource for the corresponding KMT2 gene (search terms were KMT2A, KMT2B, KMT2C, and so on). Any mutation falling in a functional domain (for example, SET and PHD) was annotated; therefore a single mutation (for example, frameshift or nonsense) may affect more than one domain. The COSMIC data do not specify whether the mutation is a 'driver' or 'passenger' mutation. KMT, histone-lysine N-methyltransferase; PHD, plant homeotic domain; RRM, RNA recognition motif.
Genetic studies in mice have demonstrated that deletion of one Kmt2a allele is not sufficient to induce leukaemic transformation or spontaneous tumorigenesis in other tissues, which is consistent with the fact that patients carrying haploinsufficient germline KMT2A mutations do not have a reported predisposition to cancer 118 . Instead, in MLL, malignant transformation requires the gain-of-function KMT2A rearrangements that lead to the production of MLLassociated fusion proteins. Therefore, additional KMT2A-independent oncogenic events are probably needed in cancers harbouring KMT2A loss-of-function mutations. This raises the question of whether KMT2A mutations initiate transformation or simply provide a permissive environment for tumorigenesis. Future exome sequencing of KMT2A in patients with cancer at various time points (early versus late, primary versus metastasis and pretreatment versus post-treatment) will be important to show when KMT2A mutations arise in the disease processes and their relationship to metastasis and relapse.
Accumulating evidence suggests that KMT2A has distinct roles after cancer onset. Although loss of one wild-type KMT2A allele is recurrent, in vitro studies show that a variety of malignant cell lines (cervical, colon and lung cancer, and choriocarcinoma) are more sensitive to KMT2A knockdown than normal cell lines 119 . Furthermore, together with hypoxia-inducible factor 1α (HIF1α), KMT2A was overexpressed in hypoxic regions of the tumour, and its knockdown reduced expression of HIF1α and vascular endothelial growth factor (VEGF) in a cervical cancer xenograft 7, 119 . KMT2A has also been shown to be a key downstream effector of the hepatocyte growth factor (HGF)-MET signalling pathway, and it facilitates metastasis in a hepatocellular carcinoma model 120 . The essential functions of wild-type KMT2A have also been demonstrated in KMT2A-rearranged MLL 121 
. Knockdown of KMT2A by short hairpin RNA (shRNA), or genetic deletion of wild-type KMT2A, leads to decreased growth of MLL-AF9 (also known as KMT2A-AF9)-transformed cells, and mice receiving KMT2A-depleted cells do not succumb to leukaemia 121 . Mechanistically, KMT2A promotes MYC transcription by binding to MYC super-enhancers 122 . KMT2A also positively regulates cell cycle regulators, including cyclin-dependent kinase inhibitor 1B (CDKN1B), CDKN2C and CDKN2A 123, 124 . Deregulation of the cell cycle is one of the common mechanisms for malignant transformation 125 . The potentially different functions of KMT2A in normal compared with malignant cells suggest that targeting KMT2A could specifically inhibit cancer cells.
KMT2B.
Analysis of currently available data reveals that there are fewer KMT2B than KMT2A non-synonymous mutations in human cancers. Endometrial, large intestine, lung, glioma and liver carcinomas contain 72% of identified mutations in the KMT2B coding region (TABLE 2) . Similar to KMT2A, mutations affecting the SET domain are the most common, and the majority of these are due to frameshift and nonsense alterations, whereas missense mutations in the SET domain are responsible for 5% of total KMT2B mutations. Of the KMT2B mutations for which zygosity is known, over 90% are heterozygous. Studies of germline or conditional Kmt2b haploinsufficiency in mice have failed to show an oncogenic propensity [126] [127] [128] [129] . Indeed, KMT2B has been generally described as a positive regulator of cell growth. Homozygous inactivation of Kmt2b in embryonic stem cells and in germline knockout mouse models resulted in proliferation defects and embryonic lethality due to increased apoptosis 126, 130 . Like KMT2A, KMT2B is recruited to the MYC enhancer through a β-catenin-dependent process to promote MYC transcription via H3K4me3 (REF. 122 ).
KMT2C and KMT2D.
To date, hundreds of KMT2C and KMT2D mutations have been identified, making these two genes among the most frequently mutated in human cancer 17 . For KMT2C, mutations are the most prevalent in lung 131 , large intestine 132 , breast 132 , endometrial and bladder carcinomas 116 , which together account for 60% of the total KMT2C mutations identified (TABLE 2) . Non-Hodgkin lymphoma 133 and medulloblastoma or other primitive neuroectodermal tumours 134 constitute nearly one-quarter of KMT2D-mutated cancers.
Box 2 | Pathogenesis of MLL
Histone-lysine N-methyltransferase 2A (KMT2A) abnormalities on chromosome 11q23 identify a group of biphenotypic leukaemias, in which leukaemic blasts express both lymphoid and myeloid surface antigens, leading to the name mixed-lineage leukaemia (MLL). KMT2A rearrangements include translocations, tandem duplications and amplifications. Together, they account for ~10% of human leukaemias, and they are associated with poor prognosis 7, 8, 114 . Most KMT2A rearrangements are balanced translocations on one allele and lead to the production of in-frame gain-of-function fusion oncoproteins. The remaining KMT2A wild-type allele and its methyltransferase activity are essential for MLL at onset or after leukaemic transformation. To date, more than 70 fusion proteins have been identified, suggesting heterogeneity in pathogenesis 7, 8, 114 . The most frequent rearrangements in MLL involve fusion partners in the ENL-associated protein (EAP) complex 173 , which account for 90% and 70% of KMT2A-rearranged acute lymphoblastic leukaemia and acute myeloid leukaemia, respectively. As EAP complex components interact with transcriptional cofactors such as RNA polymerase II associated factor 1 complex (PAF1C) 174, 175 , DOT1L [176] [177] [178] , positive transcription elongation factor b (P-TEFb)-bromodomain-containing protein 4 (BRD4) 148, 149 and chromobox 8 (CBX8)-TIP60 (Tat-interacting protein 60) 179 , it is postulated that KMT2A fusion proteins function to maintain a high level of expression of leukaemic signature genes by regulating transcription elongation. It has recently been reported that the reciprocal fusion protein (that is, AF4-MLL (also known as AF4-KMT2A)) is also able to induce acute lymphoblastic leukaemia by maintaining the ability to interact with DOT1L and P-TEFb -as well as KMT2A core subunits -and to influence the transcription elongation process 180, 181 . Mechanistic studies show that KMT2A fusion proteins are able to induce leukaemic transformation from haematopoietic stem cells in a dose-dependent manner 182 . They confer stem cell-like properties such as self-renewal, and high expression of anti-apoptotic genes and genes for drug efflux pumps 7, 8 . This function is probably mediated by a limited number of KMT2A direct targets such as HOXA9, HOXA10 and MEIS1, which in turn regulate leukaemia stem cell-specific transcription programmes 182, 183 . Interestingly, the mouse models that either constitutively express fusion proteins or produce fusion proteins by inter-chromosomal translocations from the endogenous Kmt2a locus only develop leukaemia and not other tumour types 184, 185 , suggesting that KMT2A fusion proteins have a haematopoietic-specific tumorigenic capability.
KMT2D mutations in acute myeloid leukaemia (AML), lung, large intestine and endometrial carcinomas are also widely reported 17 . Most cancer-associated KMT2C and KMT2D mutations are frameshift and nonsense alterations, which probably lead to protein truncations (TABLE 2) . Mutations that impact the SET domains and PHD domains in both proteins account for 28% and 25% of total KMT2C mutations and for 37% and 60% of total KMT2D mutations, respectively. In comparison, missense mutations in the SET domains of KMT2C and KMT2D are exceedingly rare, accounting for less than 1% of total KMT2C and KMT2D mutations. Interestingly, a disproportionally high percentage of missense mutations in the PHD domains are found in KMT2C (16%) and KMT2D (6%), and are among the highest of all types of missense mutations in the KMT2 gene family. These findings suggest that the PHD domains of KMT2C and KMT2D are probably important for tumour suppression, and thus functional characterization of these missense alterations may be a fertile area of future investigation.
Zygosity of most KMT2C and KMT2D cancer mutations is unknown. In cases in which zygosity is determined, the majority are heterozygous, whereas ~15% (53 of 322) of KMT2C and KMT2D mutations are homozygous. Interestingly, 50% of the homozygous KMT2D mutations are seen in infrequent tumours such as medulloblastoma, lymphoma (diffuse large B cell lymphoma and follicular lymphoma), kidney carcinoma and malignant melanoma. Homozygous mutations were never reported in Kabuki syndrome
, indicating that complete loss of KMT2D is not tolerated in the germ line, but can uncommonly occur somatically in a particular set of sporadic human cancers.
Compared with KMT2A and KMT2B, KMT2C and KMT2D have different functions in cancer. KMT2C and KMT2D have known negative effects on cell growth 17, 63, [135] [136] [137] [138] . Several lines of evidence suggest that KMT2C is a tumour suppressor. In D. melanogaster mosaic eye imaginal discs, clones containing loss-of-function mutant trr (an orthologue of mammalian KMT2C and KMT2D) alleles have a growth advantage over wild-type clones 135 . Nearly 50% of mice carrying a loss-of-function homozygous SET deletion Kmt2c allele develop ureter epithelial tumours 63 . Full penetrance is achieved when Kmt2c mutant alleles are introduced into a Trp53 heterozygous background 63 . However, this mouse model does not recapitulate the KMT2C haploinsufficient state observed in human bladder carcinomas, which represent ~5% of KMT2C-mutated malignancies in the COSMIC database. Interestingly, a recent report showed that adoptive transfer of haematopoietic stem cells with knockdown of Kmt2c and neurofibromin1 (Nf1) into Trp53-null mice resulted in AML 136 . This model mimics the haploinsufficient state seen in human diseases, in that KMT2C protein levels were ~50% of the control 136 . For KMT2D, the picture is more complicated. On the one hand, KMT2D interacts directly with p53 to promote expression of p53 target genes 63 . Kmt2d deletion is able to abrogate MLL-AF9-induced leukaemogenesis through a CDKN1A-dependent process 137 . On the other hand, high levels of KMT2D portend poor prognosis in patients with breast cancer, and KMT2D knockdown impairs proliferation and invasion in human breast cancer xenografts in mice, as well as in human colorectal and medullo blastoma cell lines [139] [140] [141] . These studies show that the effect of KMT2D mutations might be cell type or context dependent.
What is the potential epigenetic mechanism by which KMT2C and KMT2D exert their effects in tumori genesis? As KMT2C and KMT2D are crucial for H3K4me1 at cell type-specific distal enhancers 52, 71 , it is possible that loss-of-function KMT2C and KMT2D mutations would promote tumorigenesis by dysregulation of enhancer activity and thus, by disruption of normal developmental programmes, subversion of cell identities and/or alteration of gene networks that are regulated by tumour suppressors (for example, p53) and oncoproteins (for example, MYC). Consistent with this view, variant enhancers defined by H3K4me1 constitute a signature in colon cancers that is robustly predictive of the cancer transcriptome and is associated with cancer predisposition 96, 142 . Closer examination of the KMT2C-and KMT2D-dependent enhancer landscape in normal and cancer cells should yield important mechanistic insights.
KMT2F and KMT2G. KMT2F and KMT2G catalyse the bulk of H3K4me3 in most cells. In the COSMIC database, large intestine, lung and endometrial carcinomas and malignant melanoma together account for 62% (87 of 141) of cancers with KMT2F mutations, and endometrial, large intestine and kidney carcinomas constitute 63% (20 of 32) of KMT2G-mutant cancers. The nonsense, frameshift and missense mutations that affect the SET domain contribute up to 16% (22 of 141) of KMT2F mutations in cancer. By contrast, no missense mutations have been identified that involve the KMT2G SET domain. KMT2F mutations that affect the CFP1-interacting N-SET domain, including missense mutations, account for ~10% of total KMT2F mutations. Missense mutations in the N-terminal RNA recognition motif (RRM) domain of both KMT2F and KMT2G are reported, though at a much lower frequency. Consistent with their importance in development, among KMT2F mutations with known zygosity, only 13% were homozygous. No homozygous cancer mutations were identified for KMT2G. Although hetero zygous loss-of-function KMT2F mutations may be linked to the elevated risk of colon cancer in patients with schizophrenia 143, 144 
, these mutations (and other KMT2F and KMT2G mutations recorded in the COSMIC database ) have not yet been modelled in vivo to determine whether the human mutations induce cancers in transgenic animals.
Therapeutic targeting of KMT2 enzymes
Extensive mechanistic studies show transcriptional deregulation in MLL and have unravelled many key intermediates in disease progression from the development of novel pharmacological inhibitors for KMT2A-rearranged MLL, which provides insights into targeting KMT2s in other human cancers.
Targeting KMT2A fusion protein-dependent pathways.
Targeting the gain-of-function KMT2A rearrangements in the KMT2A fusion protein pathway represents a major translational effort. Currently, several smallmolecule inhibitors against KMT2A fusion-interacting proteins are yielding promising results in MLL (FIG. 3) . Interestingly, these inhibitors substantially alter the gene signatures of leukaemia stem cells and induce prominent myeloid differentiation of these cells in mouse models. Although the current DOT1L inhibitors still need to be improved, substantial changes in global H3K79me are detected, which are followed by inhibition of cell growth and myeloid differentiation that occur at ~10-14 days of treatment 145, 146 . Targeting DOT1L also benefits leukaemias that do not have KMT2A rearrangements 147 . Recruitment of positive transcription elongation factor-b (P-TEFb) is also a crucial step in transcriptional deregulation that leads to leukaemia 148, 149 . P-TEFb is a cyclin-dependent kinase that contains the catalytic subunit cyclin-dependent kinase 9 (CDK9), and the regulatory subunit cyclin T. P-TEFb interacts with both KMT2A fusion proteins 148, 149 and bromodomaincontaining protein 4 (BRD4) 150, 151 , which is essential for MYC expression in leukaemia cells 152, 153 . Inhibitors of CDK9 (for example, flavopiridol 154 ) and inhibitors of BRD4 (for example, JQ1 (REF. 146 ) and iBET 155 ) have shown promising results in treating MLL in mice and are in clinical trials for a variety of haematological and solid tumours (for example, ClinicalTrials. gov identifiers NCT02141828, NCT01587703 and NCT00012181). Interestingly, P-TEFb and the KMT2A fusion protein MLL-AF4 also promote cytotoxicity induced by bortezomib (a proteasome inhibitor) through PAX5-dependent activation of CDKN1B in a subset of human leukaemia 156 , suggesting that proteasome inhibitors might be an option for specific MLLs. Targeting recruitment of KMT2A fusion proteins by blocking the menin-KMT2A interaction is also an effective therapeutic strategy 57, 157 . Menin inhibitors have shown significant cellular potency in MLL by blocking expression of HOXA9 and other leukaemic genes 158 . Interestingly, as menin is also a sub-stoichiometric component of the wild-type KMT2A and KMT2B complex 56, 159 , blocking menin-KMT2A interaction leads to a reduction of both H3K4me and H3K79me at the HOXA9 locus 158 .
Targeting KMT2A methyltransferase activity. Patients with MLL usually harbour at least one wild-type KMT2A allele. Using mouse models, it has been shown that wildtype Kmt2a is required for the survival of MLL-AF9 leukaemia cells 121 . The essential function of wild-type KMT2A in MLL is mainly due to its histone methyltransferase activity, as specific blocking of KMT2A activity by the peptidomimetic MM401 (which disrupts KMT2A and WDR5 interaction 45 ) phenocopies KMT2A gene deletion in this context 45 . Although MM401 has no toxicity on normal bone marrow cells, after ~4-7 days it induces morphological changes that are analogous to those induced by DOT1L or menin inhibitors 45 . Targeting wild-type KMT2A activity may have broad applications outside MLL, including in myelodysplastic syndrome and AML that harbour KMT2A amplification or tandem duplication. Despite the importance of KMT2A activity in leukaemia, the KMT2A SET domain is in fact dispensable for leukaemia initiation 160 . This paradox is reminiscent of that of HOXA9, which is a crucial downstream target of KMT2A. Although HOXA9 is essential for MLL and is invariably upregulated in patients with MLL, Hoxa9-null bone marrow cells can still be efficiently transformed by KMT2A fusion proteins 161, 162 . It is likely that KMT2A SET activity is sufficient, but not necessary, for leukaemic transformation by KMT2A fusion proteins. We speculate
Box 3 | Germline KMT2 mutations in neuropsychiatric disorders
Germline mutations in histone-lysine N-methyltransferase 2 (KMT2) family genes are widely reported in people exhibiting intellectual disability or other neuropsychiatric features, and some of these mutations may predispose to cancer development. All of the reported germline mutations are haploinsufficient, consistent with the essential functions of KMT2 genes during development.
To date, several hundred KMT2D mutations have been associated with 55-80% of cases of Kabuki syndrome, which is characterized by distinctive facial features and intellectual disability, among other features 186 . Kabuki syndrome has been modelled in mice carrying a heterozygous allele that lacks the Kmt2d SET domain 187 .
Kmt2d
+/− mice demonstrated loss of global trimethylation of histone H3 lysine 4 (H3K4me3) and displayed intellectual disability -similar to patients with Kabuki syndrome 188 . Many patients with Kabuki syndrome show predisposition to tumours, such as pilomatricomas, synovial sarcoma, fibromyxoid sarcoma, acute lymphoblastic leukaemia, Burkitt lymphoma, neuroblastoma and hepatoblastoma 189 . Nearly three-quarters of KMT2D mutations in Kabuki syndrome have an identical pattern of domain loss to that of the somatic cancer mutations. Missense Kabuki syndrome mutations in the SET domain have been shown to affect KMT2 complex assembly 190 . Germline mutations of other KMT2 genes are also reported. De novo KMT2A germline mutations have been linked to Weidemann-Steiner syndrome, which features 'hairy elbows', intellectual disability, and distinctive facial appearance 118 , and correlates with growth retardation observed in Kmt2a +/− mice 165 . Nonsense mutations for KMT2C have been reported in Kleefstra spectrum syndrome 191 and autism spectrum disorder 192 , both of which feature intellectual disability and reduced social communication. De novo heterozygous KMT2F mutations have been linked to the common neuropsychiatric disease schizophrenia 144 . Cancer predisposition has not been described in Weidemann-Steiner syndrome, Kleefstra spectrum syndrome and autism spectrum disorder, despite the fact that patients with schizophrenia have a 190% higher risk for developing the most common KMT2F-mutant malignancy, large intestine carcinoma 143, 193 . Nature Reviews | Cancer 
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Ac that fusion proteins, by initially enhancing the expression of HOXA9, gradually drive leukaemia cells towards HOXA9 dependence that in turn requires wild-type KMT2A to maintain. In the absence of KMT2A activity, KMT2A fusion proteins could induce leukaemia through alternative pathways, consistent with rare forms of MLL that carry null KMT2A alleles 163 .
Perspectives on KMT2s in cancers
Recent studies on KMT2 mutations in human patients show that these genes are frequently altered in a broad range of cancers in addition to previously characterized haematological malignancies. Most KMT2 mutations in non-haematological cancers are heterozygous nonsense mutations that lead to truncated proteins. Despite being found as only a small subset, KMT2 missense mutations affect most conserved protein domains, including the SET and PHD domains. Mouse genetic studies show that heterozygous deletion of KMT2 genes does not lead to spontaneous tumorigenesis, suggesting that haploinsufficient KMT2 mutations alone are probably not the 'drivers' of human cancers. Future characterization and modelling of KMT2 mutations in cancer are important to delineate whether they are drivers or passengers, gainor loss-of-function, dominant or recessive mutations. Furthermore, given that the majority of cancers with KMT2 mutations still harbour at least one wild-type allele, it is also important to characterize the function of wild-type KMT2 in the malignant versus pre-malignant cells. As shown for KMT2A 121 and KMT2D
139
, the wildtype proteins could be required for cancer cell survival and thus serve as therapeutic targets.
Mechanistic studies on KMT2s show that these intrinsically different enzymes are tightly regulated by their interacting proteins, by proteolysis and by distinct chromatin recruitment mechanisms. Advances in understanding the regulation of KMT2A and its fusion oncoproteins, and their modes of action, have already led to the identification of several novel therapeutic targets, which are now being actively pursued for novel cancer therapies for MLL. We predict that similar efforts to study other KMT2 genes in cancers will lead to novel discoveries that bear clinical implications. Figure 3 | Schematic for the pathogenesis of MLL. As described in BOX 2, both wild-type histone-lysine N-methyltransferase 2A (KMT2A) and KMT2A fusion proteins contribute to the regulation of leukaemia signature genes in mixed-lineage leukaemia (MLL). Whereas KMT2A functions through its histone H3 lysine 4 (H3K4) methyltransferase activity in transcription initiation, KMT2A fusion proteins function to recruit transcription cofactors such as menin, DOT1L, positive transcription elongation factor-b (P-TEFb), LEDGF (lens epithelium-derived growth factor; also known as PSIP1), and chromobox homologue 8 (CBX8)-TIP60 (Tat-interacting protein 60; also known as KAT5) to promote transcription elongation. Small molecules targeting each of these steps (shown in boxes) have shown efficacies in MLL cell lines and represent potential therapeutic strategies 45, 145, 146, 155, 158 . Ac, acetyl group; BRD4, bromodomain-containing protein 4; CDK9, cyclin-dependent kinase 9.
